trial

Adjunctive Vortioxetine in Schizophrenia

NCTId NCT02357797
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Unknown
Enrollment 88 (estimated)
Sponsored by Northwell Health, Early Treatment Program at Lenox Hill
Primary completion 2023-10-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Unknown
Enrollment
88 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2016-02
Primary completion
2023-10-01
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Vortioxetine

Sponsors

Northwell Health, Early Treatment Program at Lenox HillLead Sponsor
TakedaCollaborator

Investigators

1
Christoph U. Correll, MDPrincipal Investigator

Sites

3 total
Lauderdale Lakes, United StatesGrand Rapids, United StatesGlen Oaks, United States

Facts & assertions

4 sourced
Enrollment
88
Phase
PHASE4
Primary Completion Date
2023-10-01
Status
UNKNOWN
relationships
The graph out of here
drug
Vortioxetine
drug
lead_sponsor
Northwell Health, Early Treatment Program at Lenox Hill
company
collaborator
Takeda
company
indication
Schizophrenia
indication
Schizophrenia
indication
Negative Symptoms
indication
investigator
Christoph U. Correll, MD
person